Phase 2 Study of ABT-510 in Patients with Previously Untreated Advanced Renal Cell Carcinoma
Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States)), Robert A. Figlin(Palmetto Hematology Oncology), Raymond A. Knight(Bridgewater State University), Rod Humerickhouse(Abbott Fund), Michael S. Gordon(Pinnacle Oncology Hematology), Jiang Qian(Johns Hopkins University), Nizar Tannir(The University of Texas MD Anderson Cancer Center), Gary Gordon, Apurva A. Desai(University of Chicago Medical Center), Maha Hussain(Northwestern University)
Cited by 89
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k